A new class of HIV-1 protease inhibitor: The crystallographic structure, inhibition and chemical synthesis of an aminimide peptide isostere

被引:28
作者
Rutenber, EE
McPhee, F
Kaplan, AP
Gallion, SL
Hogan, JC
Craik, CS
Stroud, RM
机构
[1] UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143
[3] ARQULE INC,MEDFORD,MA 02155
关键词
aspartyl protease; aminimide; protease inhibitor; human immunodeficiency virus; lead compound;
D O I
10.1016/0968-0896(96)00147-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The essential role of HIV-I protease (HIV-1 PR) in the viral life cycle makes it an attractive target for the development of substrate-based inhibitors that may find efficacy as anti-AIDS drugs. However, resistance has arisen to potent peptidomimetic drugs necessitating the further development of novel chemical backbones for diversity based chemistry focused on probing the active site for inhibitor interactions and binding modes that evade protease resistance. AQ148 is a potent inhibitor of HIV-1 PR and represents a new class of transition state analogues incorporating an aminimide peptide isostere. A 3-D crystallographic structure of AQ148, a tetrapeptide isostere, has been determined in complex with its target HIV-1 PR to a resolution of 2.5 Angstrom and used to evaluate the specific structural determinants of AQ148 potency and to correlate structure-activity relationships within the class of related compounds. AQ148 is a competitive inhibitor of HIV-1 PR with a K-i value of 137 nM. Twenty-nine derivatives have been synthesized and chemical modifications have been made at the P1, P2, P1', and P2' sites. The atomic resolution structure of AQ148 bound to HIV-1 PR reveals both an inhibitor binding mode that closely resembles that of other peptidomimetic inhibitors and specific protein/inhibitor interactions that correlate with structure-activity relationships. The structure provides the basis for the design, synthesis and evaluation of the next generation of hydroxyethyl aminimide inhibitors. The aminimide peptide isostere is a scaffold with favorable biological properties well suited to both the combinatorial methods of peptidominesis and the rational design of potent and specific substrate-based analogues. Copyright (C) 1996 Elsevier Science Ltd
引用
收藏
页码:1545 / 1558
页数:14
相关论文
共 39 条
  • [11] HYDROXYETHYLENE ISOSTERE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE - STRUCTURE ACTIVITY ANALYSIS USING ENZYME-KINETICS, X-RAY CRYSTALLOGRAPHY, AND INFECTED T-CELL ASSAYS
    DREYER, GB
    LAMBERT, DM
    MEEK, TD
    CARR, TJ
    TOMASZEK, TA
    FERNANDEZ, AV
    BARTUS, H
    CACCIAVILLANI, E
    HASSELL, AM
    MINNICH, M
    PETTEWAY, SR
    METCALF, BW
    LEWIS, M
    [J]. BIOCHEMISTRY, 1992, 31 (29) : 6646 - 6659
  • [12] THE DEVELOPMENT OF CYCLIC SULFOLANES AS NOVEL AND HIGH-AFFINITY P(2) LIGANDS FOR HIV-1 PROTEASE INHIBITORS
    GHOSH, AK
    LEE, HY
    THOMPSON, WJ
    CULBERSON, C
    HOLLOWAY, MK
    MCKEE, SP
    MUNSON, PM
    DUONG, TT
    SMITH, AM
    DARKE, PL
    ZUGAY, JA
    EMINI, EA
    SCHLEIF, WA
    HUFF, JR
    ANDERSON, PS
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (08) : 1177 - 1188
  • [13] DI(2-PYRIDYL) CARBONATE PROMOTED ALKOXYCARBONYLATION OF AMINES - A CONVENIENT SYNTHESIS OF FUNCTIONALIZED CARBAMATES
    GHOSH, AK
    DUONG, TT
    MCKEE, SP
    [J]. TETRAHEDRON LETTERS, 1991, 32 (34) : 4251 - 4254
  • [14] GRAVES BJ, 1992, STRUCTURE FUNCTION A, P455
  • [15] SELECTIVE PHOSPHINATE TRANSITION-STATE ANALOG INHIBITORS OF THE PROTEASE OF HUMAN-IMMUNODEFICIENCY-VIRUS
    GROBELNY, D
    WONDRAK, EM
    GALARDY, RE
    OROSZLAN, S
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 169 (03) : 1111 - 1116
  • [16] UREY-BRADLEY FORCE-FIELD, VALENCE FORCE-FIELD, AND ABINITIO STUDY OF INTRA-MOLECULAR FORCES IN TRI-TERT-BUTYLMETHANE AND ISOBUTANE
    HAGLER, AT
    STERN, PS
    LIFSON, S
    ARIEL, S
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1979, 101 (04) : 813 - 819
  • [17] STRUCTURE AT 2.5-A RESOLUTION OF CHEMICALLY SYNTHESIZED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE COMPLEXED WITH A HYDROXYETHYLENE-BASED INHIBITOR
    JASKOLSKI, M
    TOMASSELLI, AG
    SAWYER, TK
    STAPLES, DG
    HEINRIKSON, RL
    SCHNEIDER, J
    KENT, SBH
    WLODAWER, A
    [J]. BIOCHEMISTRY, 1991, 30 (06) : 1600 - 1609
  • [18] HTLV-III GAG PROTEIN IS PROCESSED IN YEAST-CELLS BY THE VIRUS POL-PROTEASE
    KRAMER, RA
    SCHABER, MD
    SKALKA, AM
    GANGULY, K
    WONGSTAAL, F
    REDDY, EP
    [J]. SCIENCE, 1986, 231 (4745) : 1580 - 1584
  • [19] RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS
    LAM, PYS
    JADHAV, PK
    EYERMANN, CJ
    HODGE, CN
    RU, Y
    BACHELER, LT
    MEEK, JL
    OTTO, MJ
    RAYNER, MM
    WONG, YN
    CHANG, CH
    WEBER, PC
    JACKSON, DA
    SHARPE, TR
    ERICKSONVIITANEN, S
    [J]. SCIENCE, 1994, 263 (5145) : 380 - 384
  • [20] A SYNTHESIS OF PROTECTED AMINOALKYL EPOXIDES FROM ALPHA-AMINO-ACIDS
    LULY, JR
    DELLARIA, JF
    PLATTNER, JJ
    SODERQUIST, JL
    YI, N
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1987, 52 (08) : 1487 - 1492